Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transdermal Estrogen in Women With Anorexia Nervosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03875378
Recruitment Status : Recruiting
First Posted : March 14, 2019
Last Update Posted : May 9, 2022
Sponsor:
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Pouneh K. Fazeli, MD, University of Pittsburgh

Brief Summary:
Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.

Condition or disease Intervention/treatment Phase
Anorexia Nervosa Drug: Transdermal estrogen Drug: Placebos Phase 2

Detailed Description:

Anorexia nervosa is a prevalent psychiatric with a lifetime prevalence of up to 2.2%. Among the many medical co-morbidities associated with anorexia nervosa, the most common is significant bone loss, which can persist despite weight recovery. Nearly 90% of women with anorexia nervosa have osteopenia and this low bone mass is associated with an increased fracture risk. Nearly 30% of women with anorexia nervosa report a history of a fracture and a prospective study demonstrated a 7-fold increased risk of fracture in women with anorexia nervosa compared to age-matched controls. Because anorexia nervosa is a chronic disease that can persist despite psychiatric and nutritional counseling, the bone loss and increased fracture risk can persist and lead to lifelong morbidity. Therefore, finding a treatment for bone loss associated with anorexia nervosa is of critical importance.

This 18-month randomized, placebo-controlled study will investigate in women (ages 20 to 45 years old) with anorexia nervosa whether treatment with transdermal estrogen replacement will increase bone mineral density (BMD).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, placebo-controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa
Actual Study Start Date : August 28, 2020
Estimated Primary Completion Date : August 30, 2023
Estimated Study Completion Date : August 30, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Estrogens

Arm Intervention/treatment
Experimental: Transdermal estrogen/progesterone
Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) patch applied weekly for 18 months
Drug: Transdermal estrogen
Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch

Placebo Comparator: Placebo
Placebo patch applied weekly for 18 months
Drug: Placebos
Placebo weekly patch




Primary Outcome Measures :
  1. Change in bone mineral density at 18 months [ Time Frame: Baseline, 18 months ]
    Change in lumbar spine bone mineral density at 18 months


Secondary Outcome Measures :
  1. Change in bone mineral density at hip at 18 months [ Time Frame: Baseline, 18 months ]
    Change in total hip bone mineral density at 18 months

  2. Change in bone mineral density at femoral neck at 18 months [ Time Frame: Baseline, 18 months ]
    Change in femoral neck bone mineral density at 18 months

  3. Change in parameters of bone microarchitecture at 18 months [ Time Frame: Baseline, 18 months ]
    Change in microarchitectural parameters as measured by high-resolution peripheral quantitative CT at 18 months

  4. Change in estimated bone strength at 18 months [ Time Frame: Baseline, 18 months ]
    Change in estimated bone strength as assessed by finite element analysis at 18 months

  5. Change in vertebral fractures at 18 months [ Time Frame: Baseline, 18 months ]
    Change in vertebral fractures as assessed by vertebral fracture assessment at 18 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female
  2. 19-45 years of age
  3. DSM-5 psychiatric criteria for anorexia nervosa
  4. <85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables
  5. Amenorrhea
  6. T-score of < -1.0 at spine or hip

Exclusion Criteria:

  1. Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR < 60)
  2. Personal history of venous or arterial clot
  3. History of stroke or myocardial infarction
  4. History of hypercoagulable disorder
  5. Personal history or history of a first-degree relative with breast cancer
  6. History of hereditary angioedema
  7. Any medication known to affect bone metabolism, including systemic glucocorticoids within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit
  8. Bone fracture within the prior 12 months
  9. Serum potassium < 3.0 meq/L, serum ALT > 3 times the upper limit of normal or Hemoglobin < 10 g/dL
  10. Fasting serum triglyceride level > 150 mg/dL
  11. Pregnant or breastfeeding (or desiring pregnancy within the next 18 months)
  12. Active substance abuse
  13. Elevated PTH level
  14. 25-OH vitamin D level < 20 ng/mL
  15. Low phosphorus level

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03875378


Contacts
Layout table for location contacts
Contact: Pouneh Fazeli, MD 412-648-9761 pkfazeli@pitt.edu
Contact: Shari Reynolds 412-383-0570

Locations
Layout table for location information
United States, Pennsylvania
University of Pittsburgh School of Medicine Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Pouneh K Fazeli, MD    412-648-9761    pkfazeli@pitt.edu   
Contact: Shari Reynolds    412-383-0570      
Sponsors and Collaborators
Pouneh K. Fazeli, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Layout table for investigator information
Principal Investigator: Pouneh Fazeli, MD University of Pittsburgh
Layout table for additonal information
Responsible Party: Pouneh K. Fazeli, MD, Associate Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03875378    
Other Study ID Numbers: STUDY19070395
R01HD099139 ( U.S. NIH Grant/Contract )
First Posted: March 14, 2019    Key Record Dates
Last Update Posted: May 9, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The final dataset will include self-reported demographic and behavioral data from interviews with the subjects, laboratory data from blood specimens provided and radiologic images of subjects with anorexia nervosa. Because anorexia nervosa is a psychiatric disease and we will be collecting identifying information, even though the final dataset will be stripped of identifiers prior to release for sharing, we believe that the information disclosed by the subjects should be protected in the most stringent way possible in order to prevent possible identification of subjects. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate computer technology; and 3) a commitment to destroying or returning the data after analyses are completed.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: 12 months after publication and no pre-specified end date.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Pouneh K. Fazeli, MD, University of Pittsburgh:
Bone mineral density
Estrogen
Additional relevant MeSH terms:
Layout table for MeSH terms
Anorexia
Anorexia Nervosa
Signs and Symptoms, Digestive
Feeding and Eating Disorders
Mental Disorders
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs